Safety and Efficacy Study of Sotagliflozin on Glucose Control in Participants With Type 2 Diabetes, Moderate Impairment of Kidney Function, and Inadequate Blood Sugar Control

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 787 participants.

Also called NCT03242252

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; triple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 787 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT03242252
Other papers using this trial's data
  • Efficacy and safety of sotagliflozin in patients with type 2 diabetes and stage 3 chronic kidney disease Diabetes, obesity & metabolism, 2023-06 DOI, PubMed 36782093

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Argentina, Brazil, Canada, Colombia, Germany, Hungary, Israel, Italy, Mexico, Poland, Romania, Russia, South Africa, Spain, Ukraine (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT03242252. Randomized; triple masking; primary purpose treatment. Start 2017-08-16 (actual); primary completion 2019-03-25 (actual). Results posted on 2021-06-25.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Safety and Efficacy Study of Sotagliflozin on Glucose Control in Participants With Type 2 Diabetes, Moderate Impairment of Kidney Function, and Inadequate Blood Sugar Control
Acronym
SOTA-CKD3
Condition
Type 2 Diabetes Mellitus
Condition
Chronic Kidney Disease Stage 3
Intervention (Drug)
Placebo
Intervention (Drug)
Sotagliflozin
Lead sponsor
Lexicon Pharmaceuticals (class: industry)
Collaborator
Sanofi (class: industry)

Record details

Record id
cardio:ct-nct03242252
Content hash
fc55ad45563d250af070611194c64b6d6fcb56cb3b2a2bb8b5908d3fb9ddaa83